Lars M. Wagner, MD
Appointment
Associate Professor of Clinical Pediatrics
Email
lars.wagner@cchmc.org
Phone
513-636-4266
Fax
513-636-3549
Credentials
MD: University of Kentucky, Lexington, KY 1991.
Residency: Pediatrics, University of Tennessee, Memphis, TN.
Fellowship: Pediatric Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN.
Certification: Pediatrics, 1994.
Certification: Pediatric Hematology/Oncology, 2004.
Awards and Honors
- Phi Beta Kappa
- Alpha Omega Alpha
- American Academy of Pediatrics
- Community Pediatrician Teaching Award
- General Pediatrics Teaching Award
- American Society of Pediatric Hematology/Oncology
- American Society of Clinical Oncology
- Brigid Leventhal Merit Award for Research in Pediatric Oncology, Presented by the American Society of Clinical Oncology
- Children's Oncology Group
- Children's Oncology Group Neuroblastoma Developmental Therapeutics Subcommittee
- Association of Clinical Research Professionals
- Best Doctors in America, 2008
Research
Principal investigator for:
- NANT 03-01: "A Phase I Study of Oral Irinotecan, Temozolomide, and Cefixime in Children with Recurrent/Resistant Neuroblastoma" - trial being run through the New Approaches to Neuroblastoma Therapy Consortium (NANT)
- ADVL0414: "A Phase I Study of temozolomide, Oral Irinotecan, and Vincristine for Children with Refractory Solid Tumors" - a Phase I study being run through the Children's Oncology Group
- "A Pilot study of temozolomide and O6-benzylguanine for treatment of high-grade glioma, using autolologous peripheral blood stem cells genetically modified for chemoprotection" - this is a gene therapy trial for patients with high-risk brain tumors to be run through Cincinnati Children's
Publications, Most Recent
Connect to Lars Wagner's publications on PubMed
Wagner LM, Villablanca JG, Stewart CF, Crews KR, O'Shaughnessy M, Groshen S, Reynolds CP, Park JR, Maris JM, Matthay KK. Phase I study of oral irinotecan, temozolomide, and cefixime in children with relapsed high-risk neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium study. Manuscript in preparation.
Wagner LM, Crews K, Stewart CF, Rodriguez-Galindo C, McNall-Knapp R, McAllister N, Pappo AS, Furman WL. Reducing irinotecan-associated diarrhea in children. Pediatr Blood & Cancer (in press).
Wagner LM, Garrett JK, Hill DA, Biegel JA, Ballard ET, Collins MH. Malignant rhabdoid tumor mimicking hepatoblastoma: A case report and review of the literature. Pediatr & Develop Pathol 2007; 10: 409-15.
Wagner LM, McLendon RE, Yoon KJ, Weiss BD, Billups CA, Danks MK. Targeting methylguanine-DNA methyltransferase (MGMT) in the treatment of neuroblastoma. Clin Cancer Res 2007; 13: 5418-25.
Will E, Bailey J, Balcik B, Burzynski B, Witte D, Layh-Schmitt, von Kalle C, Baum C, Sorrentino BP, Wagner LM, Kelly P, Reeves L, Williams DA. Importance of murine study design for testing toxicity of retroviral vectors in support of Phase I trials. Mol Ther 2007; 15: 782-91.
Wagner LM, McCallister N, Goldsby RE, Rausen AR, McCarville B, Albritton K. Temozolomide and intravenous irinotecan for the treatment of advanced Ewing sarcoma. Pediatr Blood & Cancer 2007; 48: 132-7.
Wagner LM, Burger RS, Guichard S, Danks MK. Pilot study to evaluate N-myc expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR. J Pediatr Hematol/Oncol 2006; 28 (10): 635-41.
Wagner LM, Billups C, Furman WL, Rao BN, Santana VM. Combined use of erythropoietin and G-CSF does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: A randomized controlled trial. J Clin Oncol 2004; 22: 1886-1893.
Wagner LM, Crews KR, Iacono L, Houghton PJ, Fuller C, McCarville B, Goldsby R, Albritton K, Stewart CF, Santana VM. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 2004; 10: 840-848.
Wagner LM, Zhou H, Brockmeyer DL, Hedlund GL. Spinal cord schwannomas mimicking drop metastases in a patient with intramedullary ependymoma and neurofibromatosis 2. J Pediatr Hematol/Oncol 2004; 26 (1): 56-59.
Presentations, Most Recent:
"Targeted therapies in early clinical trials of osteosarcoma." Advances in the Diagnosis and Management of Musculoskeletal Tumors, Cincinnati, OH, 2007.
"Does adjusting therapy based on tissue necrosis change the outcome? An overview of Children's Oncology Group Study AOST0331." Advances in the Diagnosis and Management of Musculoskeletal Tumors, Cincinnati, OH, 2007.
"Temozolomide and irinotecan for Ewing sarcoma." Children's Oncology Group Fall Meeting, Dallas, TX, 2005.
"New agents in development for supportive care in pediatric oncology." International Society of Pediatric Oncology Annual Meeting, Vancouver, CA, 2005.
"Phase I trial of BCNU, temozolomide, and O6-Benzylguanine with autologous peripheral blood stem cell support for pediatric patients with high-grade glioma." Pediatric Brain Tumor Consortium Spring Meeting, Chicago, IL, 2004.
"Use of combined irinotecan and temozolomide for high-grade glioma." Children's Oncology Group Spring Meeting, Washington, DC, 2004.
"Phase I trial of combined oral irinotecan, temozolomide and cefixime for refractory neuroblastoma." New Approaches to Neuroblastoma Therapy Consortium Spring Meeting, Santa Monica, CA, 2004.
"Phase I trial of temozolomide and irinotecan for relapsed solid tumors." Children's Oncology Group Fall Meeting, St. Louis, MO, 2002.
"New advances and old controversies in the use of hematologic growth factors." Children's Oncology Group Spring Meeting, Jacksonville, FL, 2002.
Abstracts, Most Recent
Balcik B, Leemhuis T, Reeves L, Murphy L, Wagner LM, Williams D. Clinical –scale transduction of a drug resistance gene into hematopoietic progenitor cells using a retroviral vector. 2007 Annual American Association of Blood Banks Annual Meeting, Anaheim, CA.
Wagner LM, Villablanca JG, Stewart CF, Crews KR, O'Shaughnessy MA, Groshen S, Reynolds CP, Park JR, Maris JM, Matthay KK. Phase I study of oral irinotecan and temozolomide in children with relapsed high-risk neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) Consortium study. 2007 American Society of Clinical Oncology Annual Meeting, Chicago, IL. Published in Proc Am Soc Clin Oncol 2007: 542s (abstract 9567).
Perentesis JP, Wagner LM, Ames MM, Reid JM, Stewart CF, Ingle AM, Blaney AM, Adamson PC. Phase I study of oral irinotecan, temozolomide, and vincristine for children with refractory solid tumors: A Children's Oncology Group study. 2007 American Society of Clinical Oncology Annual Meeting, Chicago, IL. Published in Proc Am Soc Clin Oncol 2007: 541s (abstract 9563).
Wagner LM, Weiss B, McLendon RE. MGMT expression is ubiquitous in primary neuroblastoma tumors. 2006 Advances in Neuroblastoma Research International Conference, Los Angeles, CA.
Wagner LM, Bush R, Remack J, Yoon K, McLendon R, Weiss B, Danks M.O6-Benzylguanine pretreatment sensitizes neuroblastoma cells to temozolomide and irinotecan regardless of the level of MGMT expression. 2006 Advances in Neuroblastoma Research International Conference, Los Angeles, CA.
Wagner LM, McCallister N, Goldsby RE, Rausen AR, McCarville B, Albritton K. Temozolomide and intravenous irinotecan for the treatment of advanced Ewing's sarcoma: A retrospective review. American Society of Clinical Oncology Annual Meeting, Orlando, FL. Published in Proc Am Soc Clin Oncol 2005; 8526a.
Book Chapters
Wagner LM. New agents in development for supportive care in pediatric oncology. International Society of Pediatric Oncology Educational Book, 2005: 29-35.
Wagner LM. Solid tumors of infancy and childhood. In: Comprehensive Pediatrics. 1st edition. Osborn LM, et al., editors. Mosby Publishing Company, 2004: 1098-1104.
Special Interests
Neuroblastoma; gene therapy; sarcoma; neuro-oncology
Related Areas
This person works in these other areas at Cincinnati Children's Hospital Medical Center:
